Clinical trial

Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)

NCT04783935

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-03-10

PhasePHASE4

Study timeline

Study start (actual)2021-03-10Date precision: day

Registry last updated2025-01-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

Mavenclad®DRUG

Sponsors & collaborators

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germanylead sponsor

Mapped research locations

BrnoCzechia2 MadridSpain1 HamburgGermany1 ValenciaSpain1 PragueCzechia1 MontpellierFrance1 StrasbourgFrance1 NaplesItaly1 StockholmSweden1 RennesFrance1 HaifaIsrael1 DresdenGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04783935 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.